Stem Cell Clinic

Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 – Cole of Duty

By Stem Cell Clinics

Researchstore.biz has released a new research report titled Global Canine Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 which offers a strategic evaluation of the market. The report presents prime parameters such as market size, revenue, sales analysis, and key drivers, and projection of the market by product, area, and use. The report delivers an in-depth analysis of the market with current and future trends. The report recognizes overall growth opportunities, industry drivers, obstacles, latest discoveries, and openings available for newcomers in the global Canine Stem Cell Therapy market.

Competitive Outlook:

The report further contains a competitive scenario of the major market players focusing on their sales revenue, customer demands, company profile, import/export scenario, business strategies that will help the emerging market segments in making major business decisions. In addition, their product portfolio, respective product applications, and product features have been emphasized in the report. The report also provides company shares and distribution shares data for the Canine Stem Cell Therapy market category and global corporate-level profiles of the key market participants.

DOWNLOAD FREE SAMPLE REPORT: https://www.researchstore.biz/sample-request/48453

NOTE: This report takes into account the current and future impacts of COVID-19 on this industry and offers you an in-dept analysis of Canine Stem Cell Therapy market.

The study profiles and examines leading companies and other prominent companies operating in the global Canine Stem Cell Therapy industry, covering: VETSTEM BIOPHARMA, VetMatrix, Aratana Therapeutics, Cell Therapy Sciences, Vetbiologics, Regeneus, ANIMAL CELL THERAPIES, Okyanos, Medivet Biologics, Magellan Stem Cells, Stemcellvet,

The far-reaching market study enlists a focused assessment of this business space and the regional landscape of this vertical. As per the report, the Canine Stem Cell Therapy market has established its presence across regions such as: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into: Allogeneic Stem Cells, Autologous Stem cells

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share market growth rate for each application, including: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

This search provides an analysis of indirect and direct sales channels, helps you to plan the right distribution strategy. The study also predicts the influence of different industry aspects on the global Canine Stem Cell Therapy market segments and regions. It delivers analysis on consumption volume, region-wise import/export analysis, and forecast Canine Stem Cell Therapy market from 2020-2025. At last, the report exhibits an analysis of leading marketing players, product specification, company profiles along with the contact details, production cost.

ACCESS FULL REPORT: https://www.researchstore.biz/report/global-canine-stem-cell-therapy-market-2020-48453

Important Aspects of Canine Stem Cell Therapy Market Report:

Customization of the Report: This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Researchstore.biz is a fully dedicated global market research agency providing thorough quantitative and qualitative analysis of extensive market research.Our corporate is identified by recognition and enthusiasm for what it offers, which unites its staff across the world.We are desired market researchers proving a reliable source of extensive market analysis on which readers can rely on. Our research team consist of some of the best market researchers, sector and analysis executives in the nation, because of which Researchstore.biz is considered as one of the most vigorous market research enterprises. Researchstore.biz finds perfect solutions according to the requirements of research with considerations of content and methods. Unique and out of the box technologies, techniques and solutions are implemented all through the research reports.

Contact Us Mark Stone Head of Business Development Phone: +1-201-465-4211 Email: [emailprotected] Web: http://www.researchstore.biz

The rest is here:
Global Canine Stem Cell Therapy Market with (Covid-19) Impact Analysis: Future Development, Business Growth and Applications to 2025 - Cole of Duty

Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers – Stockhouse

By Stem Cell Clinics

PHILADELPHIA, June 23, 2020 /PRNewswire/ -- Graham Company, one of the country's largest insurance brokerages, today announced a new partnership with Regenexx, a network of leading interventional orthopedics clinics. The partnership gives Graham Company's self-insured clients the option to offer alternative non-surgical orthopedic treatment methods, provided by Regenexx through its expansive network of physicians, as a benefit enhancement for employees. In addition, the partnership will help Graham Company's clients control and reduce overall costs of orthopedic surgery procedures for employees.

According to data from Regenexx, its procedures have effectively intervened on 70% of elective orthopedic injuries and conditions where surgery was previously the only solution.* Regenexx offers a unique approach to treating orthopedic injuries non-surgically through stem cell therapy and other regenerative medicine. Procedures performed by Regenexx's specially trained physician network involve injections of custom orthobiologics, derived from the patient's own cells and natural healing agents, to treat approximately 40 orthopedic conditions. This interventional approach enables employers to save up to 70% of orthopedic costs by reducing the number of unnecessary surgeries performed annually.

"At Graham Company, we are committed to identifying solutions to help our clients control escalating health care costs while also enhancing their benefits offerings for employees," said Debra Montella, Graham Company's Vice President of the Employee Benefits Division. "Through this partnership with Regenexx, we are now able to present our self-insured clients with a unique approach that is transforming orthopedic care and driving down costs associated with surgical procedures."

This partnership also benefits the employees of clients with self-funded plans, providing them with alternative non-surgical treatment options to address orthopedic injuries or conditions. Regenexx company data found that when employees are given the choice between an invasive orthopedic surgery or its non-invasive procedure to treat orthopedic conditions, employees chose Regenexx's procedure a majority of the time. Compared to traditional orthopedic surgeries, Regenexx procedures require less downtime for patients and are considered less costly, less invasive and less risky.

"Regenexx is looking forward to expanding our mission of producing the best possible patient outcomes for Graham Company and their clients through our innovative alternative to orthopedic surgery," said Regenexx CEO Jason Hellickson. "Our patented regenerative approach to treating common orthopedic conditions is transforming the care pathway of an orthopedic patient who can now avoid a surgical encounter with less risk and less downtime."

*This data applies only to elective orthopedic surgery without fracture-related care and acute care trauma.

About Graham Company Graham Company is one of the largest insurance and employee benefits brokers in the country, committed to enhancing employee safety and business viability through an action-oriented approach to risk management. In business for nearly 60 years, Graham Company designs customized and effective property and casualty, surety and employee benefits programs for its clients to protect employees and prevent losses. With offices in Philadelphia, New York City and Washington, D.C., Graham Company became 100 percent employee-owned through an employee stock ownership plan in 2017. Through its innovative insurance and safety training programs, Graham Company is redefining what it means to be an insurance broker. To learn more, visit http://www.grahamco.com.

GRAHAM COMPANY IS AN INSURANCE BROKER AND NOT A MEDICAL CARE PROVIDER. ANY QUESTIONS CONCERNING THIS PROCEDURE SHOULD BE REFERRED TO REGENEXX OR YOUR MEDICAL CARE PROVIDER.

About Regenexx Regenexx is a nationwide network of physicians who practice Interventional Orthopedics, a new specialty that focuses on using the most advanced regenerative protocols available as an alternative to many orthopedic surgeries. Regenexx has published roughly half of the research worldwide on the use of orthobiologics for treating orthopedic injuries, and our patented treatment lab-processing and treatment protocols allow us to achieve unmatched results. Our procedures use your body's natural healing agents including blood platelets and bone marrow concentrate to repair damaged bone, muscle, cartilage, tendons and ligaments. We believe in educating patients, offering options and encouraging people to take an active role in their own treatment. For more information on Regenexx Corporate, visit http://www.regenexxcorporate.com or call 888-547-6667. For more information on the Regenexx procedures, visit http://www.regenexx.com.

View original content:http://www.prnewswire.com/news-releases/graham-company-and-regenexx-announce-innovative-partnership-to-reduce-orthopedic-surgical-spend-for-employers-301081460.html

SOURCE Regenexx

Originally posted here:
Graham Company and Regenexx Announce Innovative Partnership to Reduce Orthopedic Surgical Spend for Employers - Stockhouse

Stem Cell Cartilage Regeneration Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 – 3rd Watch News

By Stem Cell Clinics

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Cartilage Regeneration market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Cartilage Regeneration Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Cartilage Regeneration market during the forecast period (2019-2029). It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Global Stem Cell Cartilage Regeneration Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global stem cell cartilage regeneration market report has been segmented on the basis of stem cell type, treatment, end user, and region.

Request Covid 19 Impact

Global Stem Cell Cartilage Regeneration Market: Overview

Stem cell-based therapy is important factor in functional replacement of cartilage regeneration. Stem cells are categorized into three kind of cells namely: hematopoietic stem cell, mesenchymal stem cells, and pluripotent stem cells.

Global Stem Cell Cartilage Regeneration Market: Dynamics

Rising adoption of minimally invasive surgery procedures, owing to its benefits such as lower risk and shorter duration for surgery is a key factor expected to drive growth of stem cell cartilage regeneration market over the forecast period.

In addition, increasing incidence of osteoarthritis among population across the globe, which in turn expected to support rising adoption of stem cell cartilage regeneration therapy. This factor is expected to boost growth of the target market over the forecast period.

Moreover, government initiatives such as government agencies which focusing on some policies in order to increase adoption of stem cell therapies is another factor expected to propel growth of target market over the forecast period.

However, higher treatment cost is a key factor expected to restrain growth of the global stem cell cartilage regeneration market over the forecast period. In addition, lack of skilled professionals to access stem cell sourcing, processing, or delivering these technologies is another factor expected to hamper growth of the target market over the forecast period.

Ongoing trend observed in the target market is increasing prevalence of osteoarthritis among population and rising adoption of minimally invasive surgery procedures which is turn expected to support growth of the global stem cell based cartilage regeneration market over the forecast period.

Increasing development of innovative technologies, products, and research and development (R&D) activities by key players are major factors expected to create potential revenue opportunities for the target market over the forecast period. In addition, increasing strategic partnership, merger, and acquisition activities by manufacturers are some other factors expected to create lucrative opportunities for player operating in the global market.

Global Stem Cell Cartilage Regeneration Market: Segment Analysis

Among the stem cell type segments, the mesenchymal stem cells segment is expected to register highest CAGR in the target market, owing to increasing research and development activities by various research organizations across the globe.

Global Stem Cell Cartilage Regeneration Market: Regional Analysis

The market in North America is expected to dominate in the global stem cell cartilage regeneration market in terms of revenue over the forecast period, owing to presence of key players operating in the target market such as Vericel Corporation, Osiris Therapeutics, among others and innovative stem cell based cartilage regeneration product launches, and development of new technologies across various countries in the region. In addition, rising geriatric population, which is more prone to degenerative disorders such as osteoarthritis across US is another factor expected to boost growth of the target market in this region.

The market in Asia Pacific is expected to register significant growth in terms of revenue over the forecast period, owing to stem cell based cartilage regeneration procedures are conducted by various hospital, specialty care, and clinics across India.

Global Stem Cell Cartilage Regeneration Market Segmentation:

Segmentation by stem cell type:

Hematopoietic Stem Cells (HSCs) Pluripotent Stem Cells (iPSC/ESCs) Mesenchymal Stem Cells (MSCs)

Segmentation by treatment:

Microfracture Osteochondral Transplant Autologous Chondrocyte Implantation Stem Cell Injections

Segmentation by end user:

Hospitals & Clinics Ambulatory Surgical Centers

Quick Read Table of Contents of this Report @ Global Stem Cell Cartilage Regeneration Market 2020 (Includes Business Impact of COVID-19)

Trusted Business Insights Shelly Arnold Media & Marketing Executive Email Me For Any Clarifications Connect on LinkedIn Click to follow Trusted Business Insights LinkedIn for Market Data and Updates. US: +1 646 568 9797 UK: +44 330 808 0580

More:
Stem Cell Cartilage Regeneration Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - 3rd Watch News

Stem Cell Bond Measure To Be Placed On November Ballot – California Globe

By Embryonic Stem Cells

On Monday, California Secretary of State Alex Padilla announced that a ballot measure to refund Californias stem cell agency received enough signatures and would be placed on the November 2020 ballot.

The measure, if passed, would refund the California Institute for Regenerative Medicine (CIRM) with a $5.5 billion bond to continue with stem cell research, facility construction, and training. According to the press release, much of the funding would specifically go towards research for Alzheimers, Parkinsons, stroke, epilepsy, and other brain and other central nervous system diseases and conditions.

With 685,534 signatures, 110% of the needed amount, Secretary Padilla can now officially announce the ballot placement once random sampling validates the required amount.

Stem cell research has remained controversial due the use of stem cells from human embryos, or embryonic stem cells. Federal funding for stem cell research was removed by former President George W. Bush in the 2000s, with his successor Barack Obama bringing research back in the 2010s. Despite the controversy, California created its own stem cell research institute after the passage of Proposition 71 in 2004, setting up CIRM. While still controversial, CIRMs immediate need of more funding , compounded by research quickly reducing the need to embryonic stem cells and advances in stem cell treatments for many older patients quickly brought in enough signatures for a refund initiative.

CIRM is close to shutting down, noted stem cell research advocate Gabrielle Hogan. This is badly needed funding that would pay for research for cures or repairing damage caused by Alzheimers and a number of other brain and memory related illnesses.

Its gotten a bad rap from some people because of the use of certain stem cells, but theyve mainly gone away from those that caused a furor twenty years ago. The focus is on saving people and treating people.

If we dont get this bond, which will fund us for a long time to come, then were screwed and we lose out on saving hundreds of thousands of people.

Others have continued to advocate for not continuing funding.

What if you treat someone who doesnt believe in abortion with embryonic stem cells, questioned Rita DAmico, a former nurse who opposed federal reintroduction of funding stem cell research ten years ago. It would be the same as using a medicine or treatment involving something deriving from the pig for a Muslim or Jewish patient, or giving a blood transfusion for a Jehovahs witness.

Its part of the belief, and if theyre still using it for treatments it can single some people out. This was what led it to the federal funding ban when Bush was in office after all.

The ballot measure, which has seen growing support in recent months, is expected to be validated by Secretary Padilla on Thursday.

Evan V. Symon is the Senior Editor for the California Globe. Prior to the Globe, he reported for the Pasadena Independent, the Cleveland Plain Dealer, and was head of the Personal Experiences section at Cracked. He can be reached at evan@californiaglobe.com.

View post:
Stem Cell Bond Measure To Be Placed On November Ballot - California Globe

Trending: Autologous Stem Cell Based Therapies 2020: Global Size, Supply-Demand, Product Type and End User Analysis To 2026 – Weekly Wall

By Embryonic Stem Cells

LOS ANGELES, United States: QY Research has recently published a report, titled Global Autologous Stem Cell Based Therapies Market Size, Status and Forecast 2020-2026. The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Autologous Stem Cell Based Therapies market. It informs readers about key trends and opportunities in the global Autologous Stem Cell Based Therapies market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Autologous Stem Cell Based Therapies market.

Key companies operating in the global Autologous Stem Cell Based Therapies market include , Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe, Autologous Stem Cell Based Therapies

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1889061/global-autologous-stem-cell-based-therapies-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Autologous Stem Cell Based Therapies market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Autologous Stem Cell Based Therapies Market Segment By Type:

, Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells Autologous Stem Cell Based Therapies

Global Autologous Stem Cell Based Therapies Market Segment By Application:

, Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Autologous Stem Cell Based Therapies market.

Key companies operating in the global Autologous Stem Cell Based Therapies market include , Regeneus, Mesoblast, Pluristem Therapeutics Inc, US STEM CELL, INC., Brainstorm Cell Therapeutics, Tigenix, Med cell Europe, Autologous Stem Cell Based Therapies

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1889061/global-autologous-stem-cell-based-therapies-market

TOC

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by Autologous Stem Cell Based Therapies Revenue 1.4 Market by Type 1.4.1 Global Autologous Stem Cell Based Therapies Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Embryonic Stem Cell 1.4.3 Resident Cardiac Stem Cells 1.4.4 Umbilical Cord Blood Stem Cells 1.5 Market by Application 1.5.1 Global Autologous Stem Cell Based Therapies Market Share by Application: 2020 VS 2026 1.5.2 Neurodegenerative Disorders 1.5.3 Autoimmune Diseases 1.5.4 Cardiovascular Diseases 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends 2.1 Global Autologous Stem Cell Based Therapies Market Perspective (2015-2026) 2.2 Global Autologous Stem Cell Based Therapies Growth Trends by Regions 2.2.1 Autologous Stem Cell Based Therapies Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Autologous Stem Cell Based Therapies Historic Market Share by Regions (2015-2020) 2.2.3 Autologous Stem Cell Based Therapies Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Autologous Stem Cell Based Therapies Market Growth Strategy 2.3.6 Primary Interviews with Key Autologous Stem Cell Based Therapies Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top Autologous Stem Cell Based Therapies Players by Market Size 3.1.1 Global Top Autologous Stem Cell Based Therapies Players by Revenue (2015-2020) 3.1.2 Global Autologous Stem Cell Based Therapies Revenue Market Share by Players (2015-2020) 3.1.3 Global Autologous Stem Cell Based Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global Autologous Stem Cell Based Therapies Market Concentration Ratio 3.2.1 Global Autologous Stem Cell Based Therapies Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Autologous Stem Cell Based Therapies Revenue in 2019 3.3 Autologous Stem Cell Based Therapies Key Players Head office and Area Served 3.4 Key Players Autologous Stem Cell Based Therapies Product Solution and Service 3.5 Date of Enter into Autologous Stem Cell Based Therapies Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Autologous Stem Cell Based Therapies Historic Market Size by Type (2015-2020) 4.2 Global Autologous Stem Cell Based Therapies Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026) 5.1 Global Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 5.2 Global Autologous Stem Cell Based Therapies Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Autologous Stem Cell Based Therapies Market Size (2015-2020) 6.2 Autologous Stem Cell Based Therapies Key Players in North America (2019-2020) 6.3 North America Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 6.4 North America Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 7 Europe 7.1 Europe Autologous Stem Cell Based Therapies Market Size (2015-2020) 7.2 Autologous Stem Cell Based Therapies Key Players in Europe (2019-2020) 7.3 Europe Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 7.4 Europe Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 8 China 8.1 China Autologous Stem Cell Based Therapies Market Size (2015-2020) 8.2 Autologous Stem Cell Based Therapies Key Players in China (2019-2020) 8.3 China Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 8.4 China Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 9 Japan 9.1 Japan Autologous Stem Cell Based Therapies Market Size (2015-2020) 9.2 Autologous Stem Cell Based Therapies Key Players in Japan (2019-2020) 9.3 Japan Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 9.4 Japan Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia Autologous Stem Cell Based Therapies Market Size (2015-2020) 10.2 Autologous Stem Cell Based Therapies Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 10.4 Southeast Asia Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 11 India 11.1 India Autologous Stem Cell Based Therapies Market Size (2015-2020) 11.2 Autologous Stem Cell Based Therapies Key Players in India (2019-2020) 11.3 India Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 11.4 India Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America Autologous Stem Cell Based Therapies Market Size (2015-2020) 12.2 Autologous Stem Cell Based Therapies Key Players in Central & South America (2019-2020) 12.3 Central & South America Autologous Stem Cell Based Therapies Market Size by Type (2015-2020) 12.4 Central & South America Autologous Stem Cell Based Therapies Market Size by Application (2015-2020) 13 Key Players Profiles 13.1 Regeneus 13.1.1 Regeneus Company Details 13.1.2 Regeneus Business Overview 13.1.3 Regeneus Autologous Stem Cell Based Therapies Introduction 13.1.4 Regeneus Revenue in Autologous Stem Cell Based Therapies Business (2015-2020)) 13.1.5 Regeneus Recent Development 13.2 Mesoblast 13.2.1 Mesoblast Company Details 13.2.2 Mesoblast Business Overview 13.2.3 Mesoblast Autologous Stem Cell Based Therapies Introduction 13.2.4 Mesoblast Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.2.5 Mesoblast Recent Development 13.3 Pluristem Therapeutics Inc 13.3.1 Pluristem Therapeutics Inc Company Details 13.3.2 Pluristem Therapeutics Inc Business Overview 13.3.3 Pluristem Therapeutics Inc Autologous Stem Cell Based Therapies Introduction 13.3.4 Pluristem Therapeutics Inc Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.3.5 Pluristem Therapeutics Inc Recent Development 13.4 US STEM CELL, INC. 13.4.1 US STEM CELL, INC. Company Details 13.4.2 US STEM CELL, INC. Business Overview 13.4.3 US STEM CELL, INC. Autologous Stem Cell Based Therapies Introduction 13.4.4 US STEM CELL, INC. Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.4.5 US STEM CELL, INC. Recent Development 13.5 Brainstorm Cell Therapeutics 13.5.1 Brainstorm Cell Therapeutics Company Details 13.5.2 Brainstorm Cell Therapeutics Business Overview 13.5.3 Brainstorm Cell Therapeutics Autologous Stem Cell Based Therapies Introduction 13.5.4 Brainstorm Cell Therapeutics Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.5.5 Brainstorm Cell Therapeutics Recent Development 13.6 Tigenix 13.6.1 Tigenix Company Details 13.6.2 Tigenix Business Overview 13.6.3 Tigenix Autologous Stem Cell Based Therapies Introduction 13.6.4 Tigenix Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.6.5 Tigenix Recent Development 13.7 Med cell Europe 13.7.1 Med cell Europe Company Details 13.7.2 Med cell Europe Business Overview 13.7.3 Med cell Europe Autologous Stem Cell Based Therapies Introduction 13.7.4 Med cell Europe Revenue in Autologous Stem Cell Based Therapies Business (2015-2020) 13.7.5 Med cell Europe Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

More here:
Trending: Autologous Stem Cell Based Therapies 2020: Global Size, Supply-Demand, Product Type and End User Analysis To 2026 - Weekly Wall

Mini-Organ Research Reveals What COVID-19 Does to the Body – Futurism

By Stem Cell Doctors

In order to understand how COVID-19 spreads throughout the body, ravaging it in myriad ways, doctors are growing miniature balls or organ-like tissue called organoids, and infecting them again and again.

The results, Nature News reports, are particularly troubling: the miniature lungs, livers, kidneys, hearts, intestines all showed signs of damage. The series of studies reveals with shocking clarity that COVID-19 can cause far more than a lung infection.

Of course, thats not exactly news. This harrowing list of survivors and medical workers horror stories gathered by SFGate includes heart attacks, strokes, long-term lung damage, incontinence, skin damage, and other serious complications for supposed mild cases of the coronavirus:

Thats just one of the many, many stories they gathered about the ways a road to recovery from COVID-19 is neither linear nor something that shouldnt be feared.

That said, for all their benefits, organoids are still imperfect. Per Nature, theyre far more simplistic than a full-sized organ. And because theyre not all connected in the same body, doctors can only use them to study the impacts on a single organ in isolation.

We know the cells die but we dont know how, Weill Cornell Medicine stem cell biologist Shuibing Chen told Nature of her study on miniature lungs.

Even though questions remain, its clear those impacts are serious. Various studies found that the coronavirus caused serious damage in several organs, and may lead to indirect damage in others. It also became clear that the coronavirus can infect and spread through blood vessels, leading to a more serious, widespread case.

To figure that out, biologists will need to develop more sophisticated and realistic organoids and try their experiments again, Nature reports.

It is too early to say how relevant they are, Bart Haagmans, an Erasmus MC virologist who ran a study on gut organoids, told Nature.

See the original post:
Mini-Organ Research Reveals What COVID-19 Does to the Body - Futurism

Who is Nick Cordero and how is he doing after his coronavirus battle? – The Sun

By Stem Cell Doctors

BROADWAY star Nick Cordero contracted coronavirus on March 20 of this year according to his wife Amanda Kloots.

The Tony Award-nominated actorfor Bullets over Broadway has been in the ICU since late March, with his other half keeping fans updated on his progress.

5

Earlier this year in May, Amanda tearfully revealed that Nick's condition was "going a little downhill."

Nick Cordero is a Canadian Broadway actor.

The 41-year-old has performed in the likes of A Bronx Tale The Musical, Waitress, and Rock of Ages.

He has collected several accolades for his theatre work over the years from the Outer Critics Circle and the Theatre World Awards.

Nick caught coronavirus earlier in March this year and has faced a series of ups and downs since he contracted the virus.

He was hospitalized in ICU after doctors first misdiagnosed him with pneumonia.

Nick has suffered a variety of complications as a result of COVID-19.

Doctors were not only forced to amputate his right leg because of blood clots, but the Broadway star has also had to undergo stem cell treatment to strengthen his lungs.

Nick's wife Amanda, who is single-handedly raising their one-year-old son Elvis while Nick is ill, regularly takes to Instagram to update fans on his condition.

5

In May, Amanda tearfully shared that Nick's condition was worsening.

"Nick has had a bad morning. Unfortunately, things are going a little downhill at the moment," she shared.

She added "I know that this virus is not going to get him down.

"This is not how his story ends. So just keep us in your thoughts and prayers, thank you."

A week beforehand, she announced that Nick was finally conscious after a month-long coma.

"This infection that is leftover from when he went into septic shock the last time is still in his lungs and just kind of sitting there. They are doing everything they can to clean it out every day but its just not getting better.

5

The mom-of-one also told fans doctors could "lower his vent settings" once the infection goes away.

That will begin the process of trying to get him breathing on his own.

She added: They are cleaning him out every day and hes on antibiotics, so it can happen and its gonna happen because like Ive said from the beginning, the doctor told me from the beginning, if we have a positive attitude, there are options.

"This infection is gonna go away and he is gonna get off that ventilator. And thats the only mindset that I have right now.

Nick is fighting for his life every day in that ICU and I know he isnt giving up. Were not giving up. Nobody is giving up.

Amanda, 38, recently updated fans that husband Nickhad a "great day" after visiting the actor at Cedars-Sinai hospital in LA on Sunday.

She told her Instagram followers: "He was having such a great day.

"He was more alert than I've seen him in a while and he was really following [with] his eyes a lot."

5

Amanda also revealed the sweet "little tradition" she has during her hospital visits to see Nick - playing and singing along to seventies track Our House by Crosby, Stills, Nash & Young.

She added: "I say a big prayer, hold his hand and give him a kiss and tell him we will live together in our house one day and keep fighting and it's going to happen."

5

Nick has spent a total of 82 days in ICU since he was infected with the coronavirus.

Nick's good day comes as a morale boost after Amanda revealed that a CT scan on his lungs confirmed that he would not survive a lung transplant.

Exclusive

Exclusive

"You feel like sometimes there's lots of hope and then sometimes there's not as much hope. We're basically trying to see if we can get him stable and strong enough to have more options," she said.

"It's monotonous and hard on a daily basis - very, very hard."

Read the original here:
Who is Nick Cordero and how is he doing after his coronavirus battle? - The Sun

My Friend Was Struck by ALS. Heres How Hes Fighting Back – WIRED

By Stem Cell Doctors

Brian Wallach's left hand cramped and he dropped his pen. Ten minutes later, it happened again. Annoying. He'd spent months preparing for this case. He'd joined the US Attorney's Office, a dream job, almost three years earlier. He was in the midst of prosecuting the surviving member of a group that had smuggled guns into Chicago from Indiana. The trial was a few weeks away. And now these cramps. He chalked it up to stress and moved on.

That was April 2017. On July 31, Brian and his wife, Sandra Abrevaya, had their second daughter, jaundiced but otherwise healthy, so all three stayed in the hospital a week. That's when Brian started coughing, barking, unable to finish a sentence. Sandra told him to see a doctor, so he did. He ticked off every symptom he could think of: the cough, the cramp, and also a muscle twitch in his left arm.

That physician sent Brian to a neurologist the next day. The neurologist talked through Brian's symptoms, looked at his tongueit was subtly undulating, something Brian hadn't noticed. The doctor then told him the news: He likely had amyotrophic lateral sclerosis. ALS. Lou Gehrig's disease. If he was right, the doctor said, Brian had approximately six months to live.

That was the same day Sandra and their daughter had come home from the hospital. Brian barely knew what ALS was. It seemed impossible that it would have found him, much less imposed so strict a deadline.

Brian's first call on the drive home was not to Sandra but to Nick Morris, a neurologist at the University of Maryland and a friend from college. Before he could tell Sandra the news, he needed someone to help him process it. Nick obliged, explaining that there's no one definitive test for ALSin fact, a conclusive diagnosis often requires a monthslong process of elimination.

Sandra called in the middle of that conversation, and Brian switched over. She caught something in his voice. No, everything wasn't OK, he told her. No, he couldn't say it over the phone. Yes, he was on his way home.

Sandra paced while the girls napped. When he arrived she ran out to the car and jumped into the passenger seat. Nick was still on speakerphone. I need you to get off the phone because I don't know what's going on, Sandra said to them both. And then Brian told her.

That's not that bad, right?

No, Brian replied. It is.

I'll spare you some suspense. The neurologist was right about ALS, albeit for incomplete reasons, but he was wrong about the timetable. Three years later Brian is still alive.

ALS is a cruel disease. Motor neurons in the brain and spinal cord gradually degrade and then die, robbing the sufferer of control over their muscles. Eventually patients cannot move or speak or eat or breathe. There is no cure and, except in a minority of inherited cases, no known cause. Once symptoms appearin an arm or a leg or a handthe typical survival rate is three to five years. It is fatal in virtually all cases.

Brian was one of roughly 5,000 people in the US to receive an ALS diagnosis in 2017. He's one of more than 16,000 patients living with the disease in the country today. Each has faced some version of Brian's moment in the car: mortality in sharp relief. A loved one at home who doesn't yet know. A decision about how to spend whatever time they have left.

Brian and I have known each other for three decades. Our lives have played out as variations on the same theme: good schools, bad work-life balance, two kids, settled down hundreds of miles from where we grew up. He and Sandra told me this story when I visited them last spring. We were sitting in a bedroom addition of their suburban Chicago home, built with a ramp for the inevitable day that Brian's disease will confine him to a wheelchair.

View post:
My Friend Was Struck by ALS. Heres How Hes Fighting Back - WIRED

Family of 18-year-old Doncaster boy who died of cancer raise thousands for charities that helped him – Doncaster Free Press

By Stem Cell Doctors

Joel Esan, 18, from Bessacarr, Doncaster sadly passed away on June 14, 2020 after he had been fighting a rare type of leukaemia, known as Acute Leukaemia of Ambiguous Lineage for the last two years.

Despite multiple rounds of chemotherapy, radiotherapy and a stem cell transplant from his mother, Joels aggressive form of cancer returned twice since he was first diagnosed at 16-years-old in 2018.

In April earlier this year, doctors told Joel that he only had three months to live because the leukaemia had returned and the disease had mutated meaning no further treatment could cure him.

Joel's final wish was for his family to raise money for the organisations that cared for him.

The 18-year-olds final wish was for his family to raise money for the charities that helped care for him, in particular The Teenage Cancer Trust, Clic Sargent, Laurens Legacy, Starlight and Anthony Nolan.

Joels relatives have fundraised 5,251 in just two days through their dedicated donation page to ensure other families and people like Joel can access help and support when they most need it.

His brother, Patrice Esan explained how it feels to have raised more than half of their 10,000 target.

"It just makes us so happy because we know Joel would have wanted us to raise this for those charities, Patrice said.

Joel pictured next to his sister, Charlotte, sister-in-law Zoe and brothers Patrice, Lee and Lewis.

"He would be happy looking down on us knowing we are doing a good job for him to continue his legacy and to help other people.

Joels family have expressed their thanks for the Haematology ward at The Royal Hallamshire Hospital in Sheffield who helped care for him and made the entire experience a touch less difficult to bear.

The 18-year-old spent his last moments surrounded by his loved ones in his family home.

Patrice added: He fought so hard and everything he did, he never complained about a single thing which was obviously a credit to him.

Joel (right) next to his brother Patrice (centre) and dad Femi (left).

"Even in his last moments he spoke to us and asked us to get out of bed and in those moments, he stood up in mine and my sister's arms and passed away in our arms.

"He kind of used his last strength to get up which was quite a sudden thing to happen and it was nice as a family to be together and to use his last strength to be with us.

"He was the best brother you could ask for.

Joels relatives are now urging people from Black, Asian and minority ethnic backgrounds (BAME) to register to donate their stem cells with Anthony Nolan, a charity which has a register for those who are willing to donate their stem cells to help people with blood cancers.

Its after Joel was unable to find a 100% match for his transplant and instead received cells from his Mum who was only a 50% match, which made it less effective.

White Europeans have almost 70% chance of finding a stem cell donor, while BAME people have less than 20% of finding a successful match according to Anthony Nolan.

Original post:
Family of 18-year-old Doncaster boy who died of cancer raise thousands for charities that helped him - Doncaster Free Press

Global Regenerative Medicine Market Demands, Key Players, Growth, Size and Forecast with Impact of COVID-19 (2020-2024) – Jewish Life News

By Embryonic Stem Cells

Global Regenerative Medicine Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024), provides an in-depth analysis of the global regenerative medicine market with description of market sizing and growth. The analysis includes market by value, by product, by material and by region. Furthermore, the report also provides detailed product analysis, material analysis and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global regenerative medicine market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Some of the major players operating in the global Regenerative Medicine Market are Novartis AG, Medtronic Plc, Bristol Myers Squibb (Celgene Corporation) and Smith+Nephew (Osiris Therapeutics, Inc.), whose company profiling has been done in the report. Furthermore, in this segment of the report, business overview, financial overview and business strategies of the respective companies are also provided.

Region Coverage

Company Coverage

Executive Summary

Regenerative medicines emphasis on regeneration or replacement of tissues, cells or organs of human body to cure the problem caused by disease or injury. The treatment fortify human cells to heal up or transplant stem cells into the body to regenerate lost tissues or organs or to recover impaired functionality. There are three types of stem cells that can be used in regenerative medicine: somatic stem cells, embryonic stem cells (ES cells) and induced pluripotent stem cells (iPS cells).

The regenerative medicine also has the capability to treat chronic diseases and conditions, including Alzheimers, diabetes, Parkinsons, heart disease, osteoporosis, renal failure, spinal cord injuries, etc. Regenerative medicines can be bifurcated into different product type i.e., cell therapy, tissue engineering, gene therapy and small molecules and biologics. In addition, on the basis of material regenerative medicine can be segmented into biologically derived material, synthetic material, genetically engineered materials and pharmaceuticals.

Get Free Sample Copy of this Research Report at https://www.marketreportsonline.com/contacts/requestsample.php?name=813167

The global regenerative medicine market has surged at a progressive rate over the years and the market is further anticipated to augment during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in geriatric population, rising global healthcare expenditure, increasing diabetic population, escalating number of cancer patients, rising prevalence of cardiovascular disease and surging obese population.

Though, the market faces some challenges which are hindering the growth of the market. Some of the major challenges faced by the industry are: legal obligation and high cost of treatment. Whereas, the market growth would be further supported by various market trends like three dimensional bioprinting , artificial intelligence to advance regenerative medicine, etc.

Table of Contents

Direct Purchase of this Research Report at (Single User License: US $ 900) https://www.marketreportsonline.com/contacts/purchase.php?name=813167

List of Tables

Table 1: Global Regenerative Medicine Market Players: A Financial Comparison; 2019

List of Figures.

See the original post here:
Global Regenerative Medicine Market Demands, Key Players, Growth, Size and Forecast with Impact of COVID-19 (2020-2024) - Jewish Life News

→←